Literature DB >> 23517307

Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia.

Wah-Kheong Chan1, Alexander Tong-Boon Tan, Shireene Ratna Vethakkan, Pei-Chien Tah, Anushya Vijayananthan, Khean-Lee Goh.   

Abstract

BACKGROUND AND AIM: There is currently no published study comparing prevalence of non-alcoholic fatty liver disease (NAFLD) and associated factors among diabetics of different ethnicity in the Asia-Pacific region.
METHODS: Cross-sectional study of consecutive patients in the Diabetic Clinic in University of Malaya Medical Centre. The Global Physical Activity Questionnaire and a semiquantitative food-frequency questionnaire were used to assess physical activity and dietary intake, respectively. Diagnosis of NAFLD was ultrasound-based and following exclusion of significant alcohol intake.
RESULTS: Data for 399 patients were analyzed (mean age 62.3 ± 10.5 years, 43.1% men). The racial distribution was Chinese 43.6%, Indian 33.1%, Malay 22.3%, and others 1.0%. The prevalence of NAFLD was 49.6%. On univariate analysis, factors associated with NAFLD were age < 65 years, race, obesity, central obesity, glycated hemoglobin ≥ 7.0%, and elevated serum alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase levels. Patients with low physical activity were more likely to have NAFLD (odds ratio [OR] = 1.67, 95% confidence interval [CI] = 1.06-2.63, P = 0.020). The prevalence of NAFLD was highest among Malays (60.7%), followed by Indians (51.5%), and lowest among Chinese (42.0%) consistent with higher prevalence of central obesity and higher percentage calorie intake from fat in the former groups of patients. On multivariate analysis, independent factors associated with NAFLD were central obesity (OR = 2.20, 95% CI = 1.29-3.75, P = 0.004) and elevated serum ALT level (OR = 1.98, 95% CI = 1.21-3.25, P = 0.007).
CONCLUSIONS: NAFLD was seen in half of a cohort of diabetic patients and was independently associated with central obesity and elevated serum ALT level. Prevalence of NAFLD was different and paralleled the difference in prevalence of central obesity and in percentage calorie intake from fat among the different ethnic groups.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  diabetes mellitus; dietary intake; epidemiology; ethnicity; non-alcoholic fatty liver disease; physical activity

Mesh:

Substances:

Year:  2013        PMID: 23517307     DOI: 10.1111/jgh.12204

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  29 in total

1.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

2.  How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.

Authors:  Varun Takyar; Anand Nath; Andrea Beri; Ahmed M Gharib; Yaron Rotman
Journal:  Hepatology       Date:  2017-07-27       Impact factor: 17.425

3.  Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males.

Authors:  Wah-Kheong Chan; Norhaniza Bahar; Hamizah Razlan; Anushya Vijayananthan; Pavai Sithaneshwar; Khean-Lee Goh
Journal:  Hepatol Int       Date:  2014-01-03       Impact factor: 6.047

4.  A small supernumerary marker chromosome resulting in mosaic partial tetrasomy 4q26-q31.21 in a foetus with multiple congenital malformations.

Authors:  Zhi-Tao Zhang; Wen-Xu Qi; Cai-Xia Liu; Shao-Wei Yin; Yan Zhao; Jesse Li-Ling; Yuan Lv
Journal:  J Genet       Date:  2019-03       Impact factor: 1.166

5.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 6.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Authors:  Christina C Lindenmeyer; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

7.  Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.

Authors:  Lee-Lee Lai; Shireene Ratna Vethakkan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva; Wah-Kheong Chan
Journal:  Dig Dis Sci       Date:  2019-01-25       Impact factor: 3.199

8.  Combined Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Sleeve Gastrectomy or Gastric Bypass?-a Controlled Matched Pair Study of 34 Patients.

Authors:  Adrian T Billeter; Jonas Senft; Daniel Gotthardt; Philipp Knefeli; Felix Nickel; Thilo Schulte; Lars Fischer; Peter P Nawroth; Markus W Büchler; Beat P Müller-Stich
Journal:  Obes Surg       Date:  2016-08       Impact factor: 4.129

9.  A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.

Authors:  Lauren E Mellor-Crummey; Jordan E Lake; Holly Wilhalme; Chi-Hong Tseng; Philip M Grant; Kristine M Erlandson; Jennifer C Price; Frank J Palella; Larry A Kingsley; Matthew Budoff; Wendy S Post; Todd T Brown
Journal:  J Clin Gastroenterol Hepatol       Date:  2018-07-30

Review 10.  Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?

Authors:  Mohamed H Ahmed; Nazik Elmalaika Os Husain; Ahmed O Almobarak
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.